Edwards Lifesciences Corporation $EW Shares Sold by Swiss National Bank

Swiss National Bank decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 4.6% in the 3rd quarter, Holdings Channel reports. The firm owned 1,691,000 shares of the medical research company’s stock after selling 82,100 shares during the quarter. Swiss National Bank’s holdings in Edwards Lifesciences were worth $131,509,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. True Wealth Design LLC raised its stake in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after acquiring an additional 259 shares during the period. Hantz Financial Services Inc. grew its holdings in shares of Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares during the last quarter. Rakuten Securities Inc. raised its position in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Finally, Strengthening Families & Communities LLC acquired a new position in Edwards Lifesciences during the 3rd quarter valued at approximately $34,000. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $85.93, for a total value of $974,446.20. Following the sale, the vice president owned 21,266 shares of the company’s stock, valued at $1,827,387.38. This trade represents a 34.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 60,104 shares of company stock valued at $5,084,637 over the last three months. 0.34% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

EW has been the topic of several analyst reports. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. BTIG Research restated a “buy” rating and set a $103.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. The Goldman Sachs Group reissued a “buy” rating and set a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, Evercore restated an “outperform” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 5th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $85.76 on Wednesday. The stock has a market cap of $49.81 billion, a price-to-earnings ratio of 46.86, a PEG ratio of 2.20 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The stock’s 50 day moving average price is $82.50 and its 200 day moving average price is $81.52.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same period in the previous year, the business posted $0.59 earnings per share. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.